Appendix 3

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix 3 – Characteristics of study participants

Characteristics	All participants at baseline					Cohort of participants with diabetes at baseline				
	No diabetes		Diabetes		p-value	Control (n=3292)		Intervention (n=3617)		p-value
		n		n			n		n	
Age (years), mean (sd)	60.2 (13.0)	44329	63.1 (12.47)	8829	<0.001	62.9 (12.04)	3292	62.6 (12.02)	3617	0.91
Male, n (%)	18183 (41.1%)	44264	4301 (48.8%)	8821	<0.001	1573 (47.86%)	3287	1806 (49.93%)	3617	0.25
Indigenous, n (%)	6467 (14.6%)	44335	2956 (33.5%)	8829	<0.001	1156 (35.12%)	3292	1196 (33.07%)	3617	0.65
Current / recent smoking, n (%)	7984 (21.9%)	36498	1882 (24.1%)	7814	<0.001	716 (23.87%)	3000	753 (23.39%)	3219	0.54
Systolic blood pressure (mmHg), mean (sd)	128.9 (16.8)	39278	133.1 (18.0)	8253	<0.001	133.2 (18.37)	3145	132.7 (17.18)	3409	0.40
Total cholesterol (mmol/L), mean (sd)	5.1 (1.1)	32448	4.4 (1.1)	7716	<0.001	4.3 (1.11)	2874	4.4 (1.11)	3359	0.25
HDL cholesterol (mmol/L), mean (sd)	1.5 (0.4)	28958	1.2 (0.4)	7217	<0.001	1.2 (0.37)	2690	1.2 (0.35)	3184	0.61
LDL cholesterol, mean (sd)	3.1 (0.9)	28655	2.4 (1.0)	7007	<0.001	2.3 (0.91)	2569	2.4 (1.05)	3133	0.57
Triglycerides (mmol/L), median (IQR)	1.2 (0.9, 1.7)	31868	1.6 (1.1, 2.3)	7630	<0.001	1.60 (1.10, 2.20)	2802	1.60 (1.20, 2.30)	3359	0.53
HbA1c (mmol/mol), mean (sd)	-	-	62 (3.9)	7556	-	58 (1.78)	2929	65 (4.57)	3203	0.15
Albuminuria, n (%)	745 (16.4%)	4540	1991 (38.3%)	5198	<0.001	734 (36.19%)	2028	885 (39.30%)	2252	0.78
eGFR < 60 ml/min, n (%)	3054 (9.2%)	33285	1422 (18.6%)	7638	<0.001	488 (17.11%)	2852	593 (18.08%)	3280	0.48
5-year CVD risk, n (%)										
Missing	18738 (42.3%)	44335	825 (9.3%)	8829	<0.001	285 (8.66%)	3292	270 (7.46%)	3617	0.37
<10%	16821 (37.9%)	44335	1068 (12.1%)	8829	<0.001	378 (11.48%)	3292	492 (13.60%)	3617	0.26
10-15%	2046 (4.6%)	44335	356 (4.0%)	8829	0.39	125 (3.80%)	3292	167 (4.62%)	3617	0.38
>15%	933 (2.1%)	44335	199 (2.3%)	8829	0.70	86 (2.61%)	3292	77 (2.13%)	3617	>.19
High risk condition	1449 (3.3%)	44335	4097 (46.4%)	8829	<0.001	1589 (48.27%)	3292	1703 (47.08%)	3617	0.98
Established CVD	4348 (9.8%)	44335	2284 (25.9%)	8829	<0.001	829 (25.18%)	3292	908 (25.10%)	3617	0.99
Coronary heart disease, n (%)	3380 (7.6%)	44335	1917 (21.7%)	8829	<0.001	687 (20.87%)	3292	780 (21.56%)	3617	0.53
Cerebrovascular disease, n (%)	1063 (2.4%)	44335	465 (5.3%)	8829	<0.001	148 (4.50%)	3292	180 (4.98%)	3617	0.62
Peripheral vascular disease, n (%)	299 (0.7%)	44335	198 (2.2%)	8829	<0.001	84 (2.55%)	3292	66 (1.82%)	3617	0.13
LVH recorded, n (%)	101 (0.2%)	44335	62 (0.7%)	8829	<0.001	32 (0.97%)	3292	17 (0.47%)	3617	0.11
Atrial fibrillation, n (%)	1343 (3.0%)	44335	511 (5.8%)	8829	<0.001	189 (5.74%)	3292	187 (5.17%)	3617	0.59
Heart failure, n (%)	485 (1.1%)	44335	420 (4.8%)	8829	<0.001	143 (4.34%)	3292	168 (4.64%)	3617	0.79
Appropriate CVD risk screening, n (%)	17527 (39.5%)	44335	5474 (62.0%)	8829	<0.001	2141 (65.04%)	3292	2458 (67.96%)	3617	0.64
High risk patients on appropriate treatment, n (%)	2668 (39.6%)	6730	3654 (55.5%)	6580	<0.001	1575 (62.90%)	2504	1412 (52.53%)	2688	0.32
High risk patients (no CVD) on appropriate treatment, n (%)	525 (22.0%)	2382	2252 (52.4%)	4296	<0.001	990 (59.10%)	1675	883 (49.61%)	1780	0.28
High risk patients (CVD) on appropriate treatment, n (%)	2143 (49.3%)	4348	1402 (61.4%)	2284	<0.001	585 (70.57%)	829	529 (58.26%)	908	0.50